{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-011951","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.350455+00:00","generated_at":"2026-06-06T05:44:15.357910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Replimune reports Q3 FY2024 net loss $51.1M; cash $466.4M; RP1 BLA plan for 2H 2024","bullets":["Net loss of $51.1M for Q3 FY2024, up from $39.7M in prior year; R&D expenses $42.8M vs $30.3M.","Cash, equivalents & short-term investments $466.4M as of Dec 31, 2023; cash runway extended into 2H 2026.","BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024; Phase 3 confirmatory trial to start 2H 2024.","RP2 data in uveal melanoma positive; planning for potential registrational trial in advanced uveal melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-011951","json":"https://secwatch.observer/filing/0001104659-24-011951.json","markdown":"https://secwatch.observer/filing/0001104659-24-011951.md","text":"https://secwatch.observer/filing/0001104659-24-011951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/0001104659-24-011951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/tm245513d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:44:15.357910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91025ee78fbdacc43e99e2bb71aae86395896e2f","claim":"Replimune Group, Inc. reported financial results for third quarter ended December 31, 2023.","evidence_excerpt":"On February 8, 2024, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the third quarter ended December 31, 2023 and certain corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/0001104659-24-011951-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}